Cipla Limited — Updates, 18-07-2026: General Updates
18-07-2026 | 09:32 am
18-07-2026 | 09:32 am
Cipla's US arm, InvaGen, received one USFDA Form 483 observation following a routine cGMP inspection at its NY facility. Cipla aims to address this promptly. Investors will watch for swift resolution to ensure smooth operations.
No comments yet. Be the first to comment!
